Rapport Therapeutics, Inc.
$37.14
▲
6.03%
2026-04-21 09:03:02
www.rapportrx.com
NGM: RAPP
Explore Rapport Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.9 B
Current Price
$37.14
52W High / Low
$42.27 / $7.73
Stock P/E
—
Book Value
$10.14
Dividend Yield
—
ROCE
-25.36%
ROE
-28.22%
Face Value
—
EPS
$-2.86
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
84
Beta
—
Debt / Equity
2.37
Current Ratio
26.17
Quick Ratio
26.17
Forward P/E
-8.74
Price / Sales
—
Enterprise Value
$1.15 B
EV / EBITDA
-9.3
EV / Revenue
—
Rating
Strong Buy
Target Price
$53.6
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Corcept Therapeutics Incorporated | $46.34 | 49.18 | $4.9 B | — | 6.68% | 15.02% | $91 / $28.66 | $6.11 |
| 2. | Alzamend Neuro, Inc. | $1.11 | — | $4.26 M | — | -113.32% | -2.5% | $8.22 / $0.84 | $0.57 |
| 3. | Fennec Pharmaceuticals Inc. | $6.73 | — | $232.02 M | — | -10.57% | -65.82% | $9.92 / $5.02 | $1.04 |
| 4. | Immunovant, Inc. | $28.53 | — | $5.81 B | — | -61.93% | -69.35% | $29.48 / $13.36 | $4.85 |
| 5. | MediciNova, Inc. | $1.47 | — | $71.37 M | — | -31.77% | -25.5% | $1.96 / $1.17 | $0.84 |
| 6. | Actinium Pharmaceuticals, Inc. | $1.44 | — | $42.98 M | — | -82.74% | -1.67% | $1.95 / $0.95 | $0.25 |
| 7. | RenovoRx, Inc. | $1 | — | $45.05 M | — | -176.68% | -2.26% | $1.45 / $0.7 | $0.15 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -38.51 M | -29.99 M | -29.5 M | -27.11 M | -23.52 M | — |
| Net Profit | -33.76 M | -26.93 M | -26.73 M | -24.06 M | -19.98 M | — |
| EPS in Rs | -0.71 | -0.56 | -0.56 | -0.5 | -0.42 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | — |
| Operating Profit | -125.1 M | -83.06 M | -36.18 M | — |
| Net Profit | -111.48 M | -78.31 M | -34.79 M | — |
| EPS in Rs | -2.33 | -1.64 | -0.73 | — |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 512.43 M | 314.93 M | 155.42 M | 31.6 M |
| Total Liabilities | 27.78 M | 9.51 M | 181.06 M | 41.66 M |
| Equity | 484.65 M | 305.43 M | -25.63 M | -10.06 M |
| Current Assets | 498.56 M | 309.8 M | 150.87 M | 31.27 M |
| Current Liabilities | 19.05 M | 8.77 M | 8.8 M | 1.66 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Operating CF | -87.47 M | -64.83 M | -27.18 M |
| Investing CF | -187.47 M | -170.14 M | -78.86 M |
| Financing CF | 270.79 M | 221.62 M | 145.14 M |
| Free CF | -88.09 M | -67.23 M | -28.82 M |
| Capex | -0.62 M | -2.4 M | -1.64 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue Growth % | — | — | — |
| Earnings Growth % | -42.37% | -125.11% | — |
| Profit Margin % | — | — | — |
| Operating Margin % | — | — | — |
| Gross Margin % | — | — | — |
| EBITDA Margin % | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.